CEFPODOXIME PROXETIL Drug Patent Profile
✉ Email this page to a colleague
When do Cefpodoxime Proxetil patents expire, and what generic alternatives are available?
Cefpodoxime Proxetil is a drug marketed by Aurobindo Pharma Ltd, Sandoz, Sun Pharm Inds Ltd, Alkem Labs Ltd, Anda Repository, and Aurobindo Pharma. and is included in eight NDAs.
The generic ingredient in CEFPODOXIME PROXETIL is cefpodoxime proxetil. There are ten drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefpodoxime proxetil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefpodoxime Proxetil
A generic version of CEFPODOXIME PROXETIL was approved as cefpodoxime proxetil by AUROBINDO PHARMA LTD on June 8th, 2007.
Summary for CEFPODOXIME PROXETIL
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 10 |
Raw Ingredient (Bulk) Api Vendors: | 83 |
Clinical Trials: | 2 |
Patent Applications: | 2,093 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CEFPODOXIME PROXETIL |
DailyMed Link: | CEFPODOXIME PROXETIL at DailyMed |
Recent Clinical Trials for CEFPODOXIME PROXETIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Entasis Therapeutics | Phase 1 |
Julio Ramirez | Early Phase 1 |
University of Louisville | Early Phase 1 |
Pharmacology for CEFPODOXIME PROXETIL
Drug Class | Cephalosporin Antibacterial |